Immune Therapeutics, Inc. (IMUN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Immune Therapeutics, Inc. (IMUN) trades at $0.09 with AI Score 44/100 (Grade C). Immune Therapeutics, Inc. is a healthcare company that currently does not have significant operations. Formerly known as TNI BioTech, Inc. Market cap: $7.78M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for IMUN: IMUN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMUN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMUN: the 1 perspectives are evenly split.
How is this calculated? →Immune Therapeutics, Inc. (IMUN) Healthcare & Pipeline Overview
Immune Therapeutics, Inc., formerly TNI BioTech, operates within the biotechnology sector but currently lacks significant operational activity. The company, headquartered in Orlando, Florida, focuses on the healthcare industry, though its current business activities are minimal, presenting a speculative investment profile.
What Is the Investment Thesis for IMUN?
Investing in Immune Therapeutics, Inc. (IMUN) presents a highly speculative opportunity due to the company's current lack of significant operations. With a market capitalization of $7.78M and a negative price-to-earnings ratio, traditional valuation metrics offer limited insight. The company's beta of 0.26 suggests lower volatility compared to the market. Potential catalysts include the announcement of new strategic initiatives or the acquisition of assets that could revitalize the company's operations. However, the primary risk lies in the uncertainty surrounding the company's future direction and its ability to generate revenue. Investors should carefully consider the speculative nature of this investment and the potential for significant losses.
Based on FMP financials and quantitative analysis
IMUN Key Highlights
- Market capitalization of $7.78M, indicating a micro-cap company.
- Negative P/E ratio due to the absence of significant operations and earnings.
- Beta of 0.26, suggesting lower volatility compared to the broader market.
- No dividend yield, consistent with companies in a developmental or transitional phase.
- Change of name from TNI BioTech to Immune Therapeutics, Inc. in October 2014, signaling a strategic shift.
Who Are IMUN's Competitors?
IMUN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| FWPAY Forward Pharma A/S | $300.00 | -25.09% | $7.45M | 45 |
| HBCNF HealthBeacon plc | $0.50 | +2269.67% | $8.44M | 44 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMUN's Key Strengths?
- Potential for strategic repositioning within the biotechnology sector.
- Name recognition associated with immune-related therapies.
- Low beta suggests lower volatility.
- Existing corporate structure allows for rapid deployment of new strategies.
What Are IMUN's Weaknesses?
- Lack of significant operations.
- Unclear strategic direction.
- Limited financial resources.
- Absence of revenue generation.
What Could Drive IMUN Stock Higher?
- Announcement of new strategic initiatives or partnerships.
- Acquisition of biotechnology assets or companies.
- Potential for breakthroughs in immune-related therapies.
- Changes in the regulatory landscape for biotechnology companies.
- Developments in the broader healthcare sector.
What Are the Key Risks for IMUN?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Lack of significant operations may lead to delisting or dissolution.
- Intense competition within the biotechnology sector.
- Regulatory hurdles and clinical trial risks.
- Uncertainty surrounding future funding and capital raising.
- Dependence on external factors and market conditions.
What Are the Growth Opportunities for IMUN?
- Strategic Acquisition: Immune Therapeutics could pursue strategic acquisitions of promising biotechnology assets or companies. This would provide an immediate boost to its operational capabilities and pipeline. The market for biotech acquisitions is robust, with numerous opportunities to acquire undervalued assets. Timeline: Within the next 1-2 years.
- Partnerships and Collaborations: Forming partnerships with larger pharmaceutical companies or research institutions could provide Immune Therapeutics with access to funding, expertise, and resources. Collaborative agreements are common in the biotechnology industry and can accelerate the development and commercialization of new therapies. Timeline: Ongoing.
- Focus on Niche Therapeutic Areas: Immune Therapeutics could focus on developing therapies for niche therapeutic areas with unmet medical needs. This would allow the company to differentiate itself from larger competitors and potentially achieve faster regulatory approval. The market for orphan drugs and rare disease therapies is growing rapidly. Timeline: Within the next 3-5 years.
- Development of Novel Drug Delivery Systems: Investing in the development of novel drug delivery systems could enhance the efficacy and safety of existing therapies. This would create a competitive advantage and potentially attract partnerships with pharmaceutical companies seeking to improve their product portfolios. The market for drug delivery technologies is expanding. Timeline: Within the next 3-5 years.
- Capitalizing on Immunotherapy Advancements: Given its name, Immune Therapeutics could explore opportunities in the rapidly expanding field of immunotherapy. This could involve developing novel immunotherapies for cancer or other diseases, or partnering with companies that have promising immunotherapy candidates. The immunotherapy market is experiencing significant growth. Timeline: Ongoing.
What Opportunities Does IMUN Have?
- Strategic acquisitions of promising biotechnology assets.
- Partnerships with larger pharmaceutical companies.
- Focus on niche therapeutic areas with unmet medical needs.
- Development of novel drug delivery systems.
What Threats Does IMUN Face?
- Intense competition within the biotechnology sector.
- Regulatory hurdles and clinical trial risks.
- Uncertainty surrounding future funding and capital raising.
- Potential for obsolescence of existing technologies.
What Are IMUN's Competitive Advantages?
- Currently, there is no discernible economic moat due to the lack of significant operations.
- Potential future moat could be established through intellectual property, strategic partnerships, or unique therapeutic approaches.
- Moat development dependent on successful execution of strategic initiatives.
What Does IMUN Do?
Immune Therapeutics, Inc., originally established as TNI BioTech, underwent a name change in October 2014, signaling a strategic shift that has yet to materialize into substantial operational activities. Headquartered in Orlando, Florida, the company exists within the biotechnology sector, a field known for its high-risk, high-reward potential. However, Immune Therapeutics, Inc. presently does not have significant operations, indicating a company in a developmental or transitional phase. The company's history suggests a potential pivot towards immune-related therapies, aligning with the biotechnology industry's focus on innovative healthcare solutions. Despite this, the absence of current operations raises questions about the company's strategic direction and future prospects. The company's evolution from TNI BioTech to Immune Therapeutics suggests an intention to capitalize on the growing interest in immunotherapy and related fields, but the lack of tangible business activities makes it difficult to assess its competitive positioning and long-term viability. The company's future hinges on its ability to develop and commercialize viable products or services within the biotechnology sector.
What Products and Services Does IMUN Offer?
- Formerly known as TNI BioTech, Inc.
- Changed its name to Immune Therapeutics, Inc. in October 2014.
- Headquartered in Orlando, Florida.
- Operates within the healthcare sector.
- Focuses on the biotechnology industry.
- Currently does not have significant operations.
How Does IMUN Make Money?
- Currently, the business model is not clearly defined due to the lack of significant operations.
- Potentially focused on developing or acquiring immune-related therapies.
- Future revenue generation dependent on strategic initiatives and partnerships.
What Industry Does IMUN Operate In?
Immune Therapeutics, Inc. operates within the biotechnology sector, an industry characterized by intense research and development, high regulatory hurdles, and significant growth potential. The global biotechnology market is projected to reach trillions of dollars by 2030, driven by advancements in genomics, personalized medicine, and immunotherapy. However, the industry is also highly competitive, with numerous companies vying for market share. Immune Therapeutics, Inc.'s lack of significant operations places it at a disadvantage compared to established players like BNOEF (BioNtech SE), CRBKF (CARB-X), FWPAY (Forward Pharma A/S), HBCNF (Hope Biosciences), and IPCIF (InPro Biotechnology Inc.), which have active research programs and commercialized products.
Who Are IMUN's Key Customers?
- Not applicable due to the lack of significant operations.
- Potential future customers could include patients, healthcare providers, and pharmaceutical companies.
- Customer base dependent on the development and commercialization of specific products or services.
F-Score 3/9Financial Health
Immune Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 67%Key Financial Metrics
Return on equity for Immune Therapeutics, Inc. stands at 67.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Immune Therapeutics, Inc. (IMUN) Valuation Context
Valued at $7.78M, IMUN is classified as a micro-cap stock. Relative to its peer group, IMUN's quantitative score of 44/100 is below the peer average of 62/100.
IMUN Financials
Bull Case vs Bear Case
Bull Case
- There's been chatter about potential new partnerships, fueling speculation about expanded market reach.
- Recent insider buying is often seen as a positive signal, suggesting confidence from those closest to the company.
- The community seems to be rallying around the company's long-term vision, despite short-term volatility.
- The company's focus on a niche area within therapeutics might give it an edge against larger players.
Bear Case
- The overall sentiment seems cautious, with some questioning the company's ability to scale up production.
- The small-cap nature of the company makes it susceptible to market fluctuations and investor sentiment swings.
- There are concerns about the limited information available, making it difficult to assess the company's true potential.
- Some investors are worried about the company's past performance and whether it can deliver on its promises.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IMUN Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
IMUN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMUN.
Price Targets
Wall Street price target analysis for IMUN.
IMUN MoonshotScore
What does this score mean?
The MoonshotScore rates IMUN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Noreen M. Griffin
CEO
Noreen M. Griffin serves as the CEO of Immune Therapeutics, Inc. Information regarding her detailed career history, education, and previous roles is not available in the provided data. Further research would be required to provide a comprehensive overview of her professional background and credentials.
Track Record: Due to the lack of significant operations at Immune Therapeutics, Inc., it is difficult to assess Noreen M. Griffin's track record in terms of key achievements, strategic decisions, and company milestones under her leadership. Her tenure has not yet been marked by significant operational or financial progress.
IMUN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Immune Therapeutics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may be subject to greater risks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in IMUN.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- OTC Other tier companies are subject to less regulatory oversight.
- The absence of significant operations raises concerns about the company's viability.
- Potential for fraud or manipulation is higher in the OTC market.
- Verify the company's financial statements and SEC filings (if available).
- Research the background and experience of the company's management team.
- Assess the company's business plan and strategic outlook.
- Evaluate the company's competitive positioning within the biotechnology sector.
- Determine the company's sources of funding and capital raising plans.
- Monitor news and press releases for any updates on the company's operations.
- Consult with a qualified financial advisor before making any investment decisions.
- The company's registration with the SEC (if applicable).
- The presence of a qualified management team.
- Any patents or intellectual property owned by the company.
- Strategic partnerships or collaborations with reputable organizations.
- Independent audits of the company's financial statements (if available).
Immune Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does Immune Therapeutics, Inc. do?
Immune Therapeutics, Inc. currently does not have significant operations, but it is positioned within the healthcare sector, specifically the biotechnology industry. Formerly known as TNI BioTech, Inc., the company changed its name in October 2014, suggesting a potential focus on immune-related therapies. However, the absence of current business activities makes it difficult to define its specific products or services. The company's future direction will depend on its ability to develop or acquire viable assets and execute a clear strategic plan.
What do analysts say about IMUN stock?
Due to the company's lack of significant operations and limited financial disclosure, there is currently no analyst coverage for Immune Therapeutics, Inc. (IMUN). Traditional valuation metrics such as price-to-earnings ratio are not applicable, and the company's future prospects are highly uncertain. Investors should conduct their own thorough due diligence and consider the speculative nature of this investment before making any decisions.
What are the main risks for IMUN?
The main risks for Immune Therapeutics, Inc. (IMUN) stem from its lack of significant operations and limited financial disclosure. Investing in OTC Other tier stocks carries inherent risks, including low liquidity, wide bid-ask spreads, and potential for fraud or manipulation. The company's future viability depends on its ability to secure funding, develop or acquire viable assets, and navigate the competitive biotechnology landscape. Investors should be aware of the potential for significant losses.
What are the key factors to evaluate for IMUN?
Immune Therapeutics, Inc. (IMUN) holds an AI score of 44/100 (low). Not financial advice.
How frequently does IMUN data refresh on this page?
IMUN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IMUN's recent stock price performance?
Immune Therapeutics, Inc. (IMUN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Potential for strategic repositioning within the biotechnology sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMUN overvalued or undervalued right now?
Valuing Immune Therapeutics, Inc. (IMUN) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IMUN?
Before investing in Immune Therapeutics, Inc. (IMUN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's lack of significant operations and limited public disclosure.
- AI analysis pending for IMUN.